Figure 8. Ganciclovir Intraocular Implant versus Intravenous Ganciclovir for Patients with Newly Diagnosed Cytomegalovirus Retinitis

Figure 8. Ganciclovir Intraocular Implant versus Intravenous Ganciclovir for Patients with Newly Diagnosed Cytomegalovirus Retinitis

In this randomized trial, 188 patients with AIDS and newly diagnosed cytomegalovirus retinitis received one of three regimens: ganciclovir intraocular implant delivering 1-µg/hr, ganciclovir intraocular implant delivering 2-µg/hr, or intravenous ganciclovir 5 mg/kg bid for at least 14 days, followed by 5 mg/kg once daily. The graph represents the percentage of affected eyes that progressed: 29 (39%) of 75 in the 1-µg/hr ganciclovir implant group, 35 (49%) of 71 in the 2-µg/hr ganciclovir implant group, and 53 (70%) of 76 in the intravenous ganciclovir group. The median time to progression was 221 days with the 1-µg/hr implant, 191 days with the 2-µg/hr implant, and 71 days with intravenous ganciclovir. For patients who received intravenous ganciclovir, the risk of involvement in the contralateral eye was approximately half that of those who received an implant. Extraocular CMV disease occurred in 10.3% of patients who received an implant, but in none of the patients who received intravenous ganciclovir.

This figure is based on data from Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.  N Engl J Med. 1997;337:83-90.

[Close Window]

From: HIV Web Study <www.hivwebstudy.org>
© 2006-11 University of Washington